Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.
Regulatory sandbox will speed up safety assessment of cell-based food
Latest NewsThe UK Food Standards Agency (FSA) has selected eight companies to participate in a two-year regulatory programme set to speed up market approval and safety assessment of cell-cultivated products.
Roche inks US$1.65bn obesity deal with Zealand Pharma
Latest NewsRoche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide with the Swiss pharma giant in the US and Europe and do the same for a combo of petrelintide and Roche’s GLP1/GIP receptor agonist CTT388.
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Sponsored PublicationsHigh-Quality HIV Antigens for Cutting-Edge Solutions
Novo Nordisk’s obesity drug CagriSema disappoints again
Latest NewsNovo Nordisk A/S’ combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials. Shares in Novo Nordisk closed down 8% after the data became public.
Roche unveils completely new sequencing approach
Associations, Latest NewsRoche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina.
ADC maker Callio Therapeutics secures US$187m in Series A round
Latest NewsInvestment company Frazier Life Sciences has launched the virtual ADC company Callio Therapeutics Inc by licencing Hummingbird Bioscience’s TopDDRive dual payload ADC technology and co-leading a US$187m financing round with French Jeito Capital and other investors.
Kinase inhibitors: Promising therapeutics for neurodegenerative diseases
Sponsored PublicationsNeurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.
EU Commission presents Clean Industrial Deal
Latest NewsThe European Commission has presented its long-awaited Clean Industrial Deal, which aims at replacing its Green Deal in times of geopolitical tensions, slow economic growth and technological competition with “a transformational business plan” that makes the world’s 2nd largest economic bloc future-proof, sustainable while improving global competitiveness.
Gene therapy manufacturing: Fuse Vectors secures US$5.2m
Latest NewsFuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
ECIS TEERZ from Applied BioPhysics
ProductsDunn Labortechnik presents the new TEERZ device from Applied BioPhysics.